{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:12:02Z","timestamp":1793995922748,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012212","name":"Billi and Bernie Marcus Foundation","doi-asserted-by":"publisher","award":["2422"],"award-info":[{"award-number":["2422"]}],"id":[{"id":"10.13039\/100012212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Various types of cellular injection have become a popular and costly treatment option for patients with knee osteoarthritis despite a paucity of literature establishing relative efficacy to each other or corticosteroid injections. Here we aimed to identify the safety and efficacy of cell injections from autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic human umbilical cord tissue-derived mesenchymal stromal cells, in comparison to corticosteroid injection (CSI). The study was a phase 2\/3, four-arm parallel, multicenter, single-blind, randomized, controlled clinical trial with 480 patients with a diagnosis of knee osteoarthritis (Kellgren\u2013Lawrence II\u2013IV). Participants were randomized to the three different arms with a 3:1 distribution. Arm 1: autologous bone marrow aspirate concentrate (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009120), CSI (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940); arm 2: umbilical cord tissue-derived mesenchymal stromal cells (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009120), CSI (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940); arm 3: stromal vascular fraction (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009120), CSI (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940). The co-primary endpoints were the visual analog scale pain score and Knee injury and Osteoarthritis Outcome Score pain score at 12\u2009months versus baseline. Analyses of our primary endpoints, with 440 patients, revealed that at 1\u2009year post injection, none of the three orthobiologic injections was superior to another, or to the CSI control. In addition, none of the four groups showed a significant change in magnetic resonance imaging osteoarthritis score compared to baseline. No procedure-related serious adverse events were reported during the study period. In summary, this study shows that at 1\u2009year post injection, there was no superior orthobiologic as compared to CSI for knee osteoarthritis. ClinicalTrials.gov Identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03818737\">NCT03818737<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02632-w","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T13:03:18Z","timestamp":1698930198000},"page":"3120-3126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-0126","authenticated-orcid":false,"given":"Ken","family":"Mautner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Akard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won C.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Boggess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-2289","authenticated-orcid":false,"given":"Paramita","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-2617","authenticated-orcid":false,"given":"Kirk A.","family":"Easley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-5877","authenticated-orcid":false,"given":"Greg","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0279","authenticated-orcid":false,"given":"Linda","family":"Kippner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Kurtenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kurtzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Amadeus","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnendu","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verle","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Yeago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Drissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"2632_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.gene.2013.05.069","volume":"527","author":"AS Lee","year":"2013","unstructured":"Lee, A. S. et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene 527, 440\u2013447 (2013).","journal-title":"Gene"},{"key":"2632_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","volume":"66","author":"KE Barbour","year":"2017","unstructured":"Barbour, K. E., Helmick, C. G., Boring, M. & Brady, T. J. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation\u2014United States, 2013\u20132015. Morb. Mortal. Wkly Rep. 66, 246\u2013253 (2017).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"2632_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/CEOR.S302289","volume":"13","author":"AV Bedenbaugh","year":"2021","unstructured":"Bedenbaugh, A. V., Bonafede, M., Marchlewicz, E. H., Lee, V. & Tambiah, J. Real-world health care resource utilization and costs among US patients with knee osteoarthritis compared with controls. Clinicoecon. Outcomes Res. 13, 421\u2013435 (2021).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"2632_CR4","doi-asserted-by":"publisher","unstructured":"Buckwalter, J. A., Saltzman, C., & Brown, T. The impact of osteoarthritis: implications for research. Clin. Orthop. Relat. Res. https:\/\/doi.org\/10.1097\/01.blo.0000143938.30681.9d (2004).","DOI":"10.1097\/01.blo.0000143938.30681.9d"},{"key":"2632_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.arcmed.2020.08.006","volume":"52","author":"DE Rodriguez-Fuentes","year":"2021","unstructured":"Rodriguez-Fuentes, D. E. et al. Mesenchymal stem cells current clinical applications: a systematic review. Arch. Med. Res. 52, 93\u2013101 (2021).","journal-title":"Arch. Med. Res."},{"key":"2632_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3390\/genes13060949","volume":"13","author":"V Molnar","year":"2022","unstructured":"Molnar, V. et al. Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: a narrative review. Genes 13, 949 (2022).","journal-title":"Genes"},{"key":"2632_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/path.2469","volume":"217","author":"AI Caplan","year":"2009","unstructured":"Caplan, A. I. Why are MSCs therapeutic? New data: new insight. J. Pathol. 217, 318\u2013324 (2009).","journal-title":"J. Pathol."},{"key":"2632_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/03635465211053893","volume":"51","author":"KI Kim","year":"2023","unstructured":"Kim, K. I., Kim, M. S. & Kim, J. H. Intra-articular injection of autologous adipose-derived stem cells or stromal vascular fractions: are they effective for patients with knee osteoarthritis? A systematic review with meta-analysis of randomized controlled trials. Am. J. Sports Med 51, 837\u201348. (2023).","journal-title":"Am. J. Sports Med"},{"key":"2632_CR9","doi-asserted-by":"publisher","unstructured":"Shapiro, S. A., Kazmerchak, S. E., Heckman, M. G., Zubair, A. C. & O\u2019Connor, M. I. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am. J. Sports Med. https:\/\/doi.org\/10.1177\/0363546516662455 (2016).","DOI":"10.1177\/0363546516662455"},{"key":"2632_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1735242","volume":"2019","author":"B Di Matteo","year":"2019","unstructured":"Di Matteo, B. et al. Minimally manipulated mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review of clinical evidence. Stem Cells Int. 2019, 1\u201314 (2019).","journal-title":"Stem Cells Int."},{"key":"2632_CR11","doi-asserted-by":"publisher","first-page":"e0175449-e","DOI":"10.1371\/journal.pone.0175449","volume":"12","author":"M Yubo","year":"2017","unstructured":"Yubo, M. et al. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis. PLoS ONE 12, e0175449-e (2017).","journal-title":"PLoS ONE"},{"key":"2632_CR12","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1177\/0363546517735844","volume":"46","author":"JA McIntyre","year":"2018","unstructured":"McIntyre, J. A., Jones, I. A., Han, B. & Vangsness, C. T. Intra-articular mesenchymal stem cell therapy for the human joint: a systematic review. Am. J. Sports Med. 46, 3550\u20133563 (2018).","journal-title":"Am. J. Sports Med."},{"key":"2632_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/0363546519899923","volume":"48","author":"JR Garza","year":"2020","unstructured":"Garza, J. R. et al. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: a double-blinded prospective randomized controlled clinical trial. Am. J. Sports Med. 48, 588\u201398. (2020).","journal-title":"Am. J. Sports Med."},{"key":"2632_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13018-023-03841-2","volume":"18","author":"A Pintore","year":"2023","unstructured":"Pintore, A. et al. Intra-articular injection of bone marrow aspirate concentrate (BMAC) or adipose-derived stem cells (ADSCs) for knee osteoarthritis: a prospective comparative clinical trial. J. Orthop. Surg. Res 18, 350 (2023).","journal-title":"J. Orthop. Surg. Res"},{"key":"2632_CR15","doi-asserted-by":"publisher","first-page":"495S","DOI":"10.1177\/1947603520976767","volume":"13","author":"L Becktell","year":"2021","unstructured":"Becktell, L. et al. Proteomic analysis and cell viability of nine amnion, chorion, umbilical cord, and amniotic fluid-derived products. Cartilage 13, 495S\u2013507S (2021).","journal-title":"Cartilage"},{"key":"2632_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1177\/0363546519829034","volume":"47","author":"AJ Panero","year":"2019","unstructured":"Panero, A. J., Hirahara, A. M., Andersen, W. J., Rothenberg, J. & Fierro, F. Are amniotic fluid products stem cell therapies? A study of amniotic fluid preparations for mesenchymal stem cells with bone marrow comparison. Am. J. Sports Med 47, 1230\u20131235 (2019).","journal-title":"Am. J. Sports Med"},{"key":"2632_CR17","first-page":"121","volume":"24","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. Mesenchymal stem cells in knee osteoarthritis treatment: a systematic review and meta-analysis. J. Orthop. Transl. 24, 121\u2013130 (2020).","journal-title":"J. Orthop. Transl."},{"key":"2632_CR18","doi-asserted-by":"publisher","first-page":"e23343","DOI":"10.1097\/MD.0000000000023343","volume":"99","author":"W Ma","year":"2020","unstructured":"Ma, W. et al. Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Medicine 99, e23343 (2020).","journal-title":"Medicine"},{"key":"2632_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s00264-016-3162-y","volume":"40","author":"CJ Centeno","year":"2016","unstructured":"Centeno, C. J. et al. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int. Orthop. 40, 1755\u20131765 (2016).","journal-title":"Int. Orthop."},{"key":"2632_CR20","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2106\/JBJS.M.00261","volume":"95","author":"P Hernigou","year":"2013","unstructured":"Hernigou, P. et al. Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate. J. Bone Jt Surg. Am. 95, 2215\u20132221 (2013).","journal-title":"J. Bone Jt Surg. Am."},{"key":"2632_CR21","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00590-013-1393-9","volume":"24","author":"JD Kim","year":"2014","unstructured":"Kim, J. D. et al. Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee. Eur. J. Orthop. Surg. Traumatol. 24, 1505\u20131511 (2014).","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"2632_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sctm.18-0285","volume":"8","author":"K Mautner","year":"2019","unstructured":"Mautner, K., Bowers, R., Easley, K., Fausel, Z. & Robinson, R. Functional outcomes following microfragmented adipose tissue versus bone marrow aspirate concentrate injections for symptomatic knee osteoarthritis. Stem Cells Transl. Med 8, 1149\u201356 (2019).","journal-title":"Stem Cells Transl. Med"},{"key":"2632_CR23","doi-asserted-by":"publisher","first-page":"1759720X2110666","DOI":"10.1177\/1759720X211066689","volume":"14","author":"MS Fazeli","year":"2022","unstructured":"Fazeli, M. S., McIntyre, L., Huang, Y. & Chevalier, X. Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence. Ther. Adv. Musculoskelet. Dis. 14, 1759720X211066689 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"2632_CR24","doi-asserted-by":"publisher","first-page":"185S","DOI":"10.1177\/1947603520906597","volume":"13","author":"D Previtali","year":"2021","unstructured":"Previtali, D. et al. The long-lasting effects of \u2018placebo injections\u2019 in knee osteoarthritis: a meta-analysis. Cartilage 13, 185S\u2013196SS (2021).","journal-title":"Cartilage"},{"key":"2632_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/M15-0623","volume":"163","author":"RR Bannuru","year":"2015","unstructured":"Bannuru, R. R. et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163, 365\u2013372 (2015).","journal-title":"Ann. Intern. Med."},{"key":"2632_CR26","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1093\/bioinformatics\/btac582","volume":"38","author":"B Phipson","year":"2022","unstructured":"Phipson, B. et al. propeller: testing for differences in cell type proportions in single cell data. Bioinformatics 38, 4720\u20134726 (2022).","journal-title":"Bioinformatics"},{"key":"2632_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1477-7525-1-64","volume":"1","author":"EM Roos","year":"2003","unstructured":"Roos, E. M. & Lohmander, L. S. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual. Life Outcomes 1, 64 (2003).","journal-title":"Health Qual. Life Outcomes"},{"key":"2632_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MRR.0b013e3282fc0f93","volume":"31","author":"AM Boonstra","year":"2008","unstructured":"Boonstra, A. M., Schiphorst Preuper, H. R., Reneman, M. F., Posthumus, J. B. & Stewart, R. E. Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain. Int. J. Rehabil. Res. 31, 165\u2013169 (2008).","journal-title":"Int. J. Rehabil. Res."},{"key":"2632_CR29","first-page":"364","volume":"25","author":"XZ Wang","year":"2012","unstructured":"Wang, X. Z. et al. Study on the diagnostic value of whole-organ magnetic resonance imaging score (WORMS) in knee osteoarthritis. Zhongguo Gu Shang 25, 364\u2013368 (2012).","journal-title":"Zhongguo Gu Shang"},{"key":"2632_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/ard.2006.066183","volume":"67","author":"DJ Hunter","year":"2008","unstructured":"Hunter, D. J. et al. The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). Ann. Rheum. Dis. 67, 206\u2013211 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"2632_CR31","unstructured":"Diggle, P. J., Liang, K. Y. & Zeger, S. L. Analysis of longitudinal data. 68\u201369 (Clarendon Press, 1994)."},{"key":"2632_CR32","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","volume":"9","author":"SY Chen","year":"2017","unstructured":"Chen, S. Y., Feng, Z. & Yi, X. A general introduction to adjustment for multiple comparisons. J. Thorac. Dis. 9, 1725\u20131729 (2017).","journal-title":"J. Thorac. Dis."}],"updated-by":[{"DOI":"10.1038\/s41591-023-02776-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02632-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02632-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02632-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T02:02:55Z","timestamp":1703296975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02632-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2632"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02632-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"13 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-023-02776-9","URL":"https:\/\/doi.org\/10.1038\/s41591-023-02776-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Several of our authors work for Sanford Health. Sanford Health has a financial interest in InGeneron, Inc., the SVF company used in this study. None of the individual physician has a financial conflict or relationship with InGeneron, Inc. K.M. is a consultant for Lipogems, which is a micronized fat company, not used in this current study. P.C., G.G., L.K., J.K., K.R. and C.Y. all receive separate grant\/salary support from the Marcus Foundation, who funded this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}